Rivaroxaban for thromboprophylaxis in acutely ill medical patients

New England Journal of Medicine

Volumn 368, Issue 6, 2013, Pages 513-523

  Cohen, Alexander T ^a   Spiro, Theodore E ^b   Büller, Harry R ^d   Haskell, Lloyd ^c   Hu, Dayi ^e   Hull, Russell ^f   Mebazaa, Alexandre ^g   Merli, Geno ^h   Schellong, Sebastian ⁱ   Spyropoulos, Alex C ^j   Tapson, Victor ^k  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b BAYER CORPORATION   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^f FOOTHILLS HOSPITAL   (Canada)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h Thomas Jefferson Medical School   (United States)

ⁱ ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^j DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^k DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; PLACEBO; RIVAROXABAN;

ACUTE DISEASE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERBILIRUBINEMIA; LUNG EMBOLISM; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMORRHAGE; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TRACHEAL HEMORRHAGE; VENOUS THROMBOEMBOLISM;

EID: 84873514413     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1111096     Document Type: Article

References (15)

1. Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005;94:750-9.
2. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-20.
3. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004;164:963-8.
4. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007;146:278-88.
5. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800.
6. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. Am J Respir Crit Care Med 2000; 161:1109-14.
7. Leizorovicz A, Cohen AT, Turpie AGG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004;110:874-9.
8. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325-9.
9. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:Suppl:381S-453S.
10. Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007;167:1471-5.
11. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 2010;153:8-18.
12. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011;365:2167-77.
13. Cohen AT, Spiro TE, Büller HR, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011;31:407-16.
14. Hochberg Y, Hommel G. Simes' test of multiple hypotheses. In: Kotz S, ed. Encyclopedia of statistical sciences, update volume 2. New York: Wiley, 1998:418-22.
15. Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011;139:69-79.